Carboplatin and docetaxel in advanced non-small-cell lung cancer: Results of a multicenter phase II study

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 5, 2004, Pages 439-444

  Ramalingam, Sakkaraiappan ^a   Dobbs, Tracy W ^b   Einzig, Avi I ^c   Wojtowicz Praga, Slawomir ^d   Cascino, Marianne ^d   Bonomi, Phillip ^e   Belani, Chandra P ^a,f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Baptist Medical Center   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d SANOFI   (France)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Carboplatin; Docetaxel; First line chemotherapy; Non small cell lung cancer; NSCLC

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; DOCETAXEL; GRANISETRON; ONDANSETRON;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HISTOLOGY; HUMAN; INFECTION; INOPERABLE CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUROSENSORY DISORDER; NEUROTOXICITY; NEUTROPENIA; NONHEMATOLOGICAL TOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TOXICITY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS;

EID: 2142643683     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0752-3     Document Type: Article

References (28)

1. Jemal A, Murray T, Samuels A, et al (2003) Cancer Statistics, 2003. CA Cancer J Clin 53:5-26
2. Mountain CF, Dresler CM (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718-1723
3. NSCLC Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
4. Wozniak AJ, Crowley JJ, Balcerzak SP, et al (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16:2459-2465
5. Schiller J, Harrington D, Belani CP, et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
6. Kelly K, Crowley J, Bunn PA, et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19:3210-3218
7. Klastersky J, Sculier JP, Lacroix H, et al (1990) A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 8:1556-1562
8. Rosell R, Gatzemeier U, Betticher DC, et al (2002) Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539-1549
9. Cerny T, Kaplan S, Pavlidis N, et al (1994) Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 70:384-387
10. Francis PA, Rigas JR, Kris MG (1994) Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12:1232-1237
11. Kunitoh H, Watanabe K, Onoshi T, et al (1996) Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 14:1649-1655
12. Le Chevalier T, Monnier A, Douillard JY, et al (1998) Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 34:2032-2036
13. Georgoulias V, Androulakis N, Dimopoulos AM, et al (1998) First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 9:331-334
14. Zalcberg J, Millward M, Bishop J, et al (1998) Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 16:1948-1953
15. Belani CP, Bonomi P, Dobbs TW, et al (1999) Docetaxel and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC): a multicenter phase II trial. Clin Lung Cancer 1:144-150
16. Belani CP, Hadeed V, Ramanathan RK, et al (1997) Docetaxel and carboplatin: a phase I and pharmacokinetic trial for advanced non-hematologic malignancies. Proc Am Soc Clin Oncol 16:220a
17. Belani CP, Einzig A, Bonomi P, et al (2000) Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 11:673-678
18. Calvert AH, Newell DR, Grumbrell LA, et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756
19. Jodrell DI, Egorin MJ, Canetta RM, et al (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528
20. Jakobsen A, Bertelsen K, Anderson JE, et al (1997) Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 15:193-198
21. Childs WJ, Nicholls EJ, Horwich A, et al (1992) The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumors of the testis. Ann Oncol 3:291-296
22. Zarogoulidis K, Kontakiotis T, Hatziapostolou P, et al (2001) A phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer 32:281-287
23. Schuette W, Bork I, Wollschlager B, et al (2001) Combination chemotherapy with docetaxel and carboplatin for advanced non-small cell lung cancer. Clin Drug Invest 21:161-168
24. Fossella F, Pereira JR, von Pawel J, et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer, the TAX 326 study group. J Clin Oncol 21:3016-3024
25. Millward M, Boyer MJ, Lehnert M, et al (2003) Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 14:449-454
26. Arcenas A, Anderson A, Krasnow S, et al (1999) Docetaxel/ carboplatin combination therapy for stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 18:495a
27. Jahanzeb M, Sarna G, Hirsch R, et al (2000) A multicenter phase II trial of carboplatin and docetaxel in previously untreated advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol 19:514a
28. Harvey J, Windsor K, Lasker J, et al (2000) A phase II study of docetaxel and carboplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 19:511a